# US 9,518,056 B2 · Inhibitors of influenza viruses replication

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,056 B2
- Document ID: US9518056B2
- Status: Granted
- Kind: B2
- Application number: 14/929,634
- Filed: 2015-11-02
- Published: 2016-06-02
- Granted: 2016-12-13
- Earliest claimed: 2009-06-17
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Paul S. Charifson; Michael P. Clark; Upul K. Bandarage; Randy S. Bethiel; John J. Court; Hongbo Deng; Ioana Davies; John P. Duffy; Luc J. Farmer; Huai Gao; Wenxin Gu; Dylan H. Jacobs; Joseph M. Kennedy; Mark W. Ledeboer; Brian Ledford; Francois Maltais; Emanuele Perola; Tiansheng Wang; M. Woods Wannamaker; Randal Byrn; Yi Zhou; Chao Lin; Min Jiang; Steven Jones; Ursula A. Germann; Francesco G. Salituro; Ann Dak-Yee Kwong
- Web page: https://patentgrep.com/patent/US9518056B2

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 471/04: Ortho-condensed systems
- C07D 239/30: Halogen atoms or nitro radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

## Claims

### Claim 1

A compound 1070:

### Claim 2

A pharmaceutical composition comprising a compound 1070:
and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 3

A pharmaceutically acceptable salt of a compound 1070:

### Claim 4

A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound 1070:
and a pharmaceutically acceptable carrier, adjuvant, or vehicle.